Endostatin: a promising biomarker in the cardiovascular continuum?
Biomark Med
; 11(10): 905-916, 2017 Oct.
Article
in En
| MEDLINE
| ID: mdl-28976780
The current review article aims to provide an up-to-date summary of previous studies in humans that have reported the association between circulating endostatin levels and different cardiovascular phenotypes. We also aim to provide suggestions for future directions of future research evaluating endostatin as a clinically relevant cardiovascular biomarker. With a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population. Circulating endostatin seems to be a promising biomarker for cardiovascular pathology, but there is not enough evidence to date to support the use of endostatin measurements in clinical practice.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Endostatins
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Biomark Med
Journal subject:
BIOQUIMICA
/
MEDICINA
Year:
2017
Document type:
Article
Affiliation country:
Sweden
Country of publication:
United kingdom